Travere Therapeutics Inc Stock Price, News & Analysis

Travere Therapeutics (NASDAQ: TVTX) reported strong Q2 2025 financial results, highlighted by significant growth in FILSPARI sales. The company achieved total revenue of $114.4 million, including net product sales of $94.8 million. FILSPARI's U.S. net sales grew 165% year-over-year to $71.9 million, with 745 new patient start forms received.

Key developments include FDA acceptance of FILSPARI's sNDA for FSGS with a PDUFA date of January 13, 2026, and an upcoming PDUFA date of August 28, 2025, for REMS modification in IgAN treatment. The company ended Q2 with $319.5 million in cash and equivalents. Net loss improved to $12.8 million ($0.14 per share) compared to $70.4 million in Q2 2024.

Travere Therapeutics (NASDAQ: TVTX) has announced its participation in four upcoming investor conferences in August and September 2025. The company will present at the Canaccord Genuity Growth Conference (August 13), Citi's Biopharma Back to School Conference (September 2), Wells Fargo Healthcare Conference (September 3), and Cantor Global Healthcare Conference (September 4).

All presentations will be available via live webcast on Travere's investor relations website, with replays accessible for 30 days after each event.

Travere Therapeutics (NASDAQ: TVTX) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, after U.S. markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update.

Investors can access the webcast and dial-in information through Travere's investor relations website at ir.travere.com/events-and-presentations. A replay of the webcast will be available on the company's website for 30 days following the live presentation.

Travere Therapeutics (NASDAQ: TVTX) announced inducement equity grants for 17 new employees. The grants consist of restricted stock units (RSUs) covering 121,700 shares of common stock. These RSUs were granted outside the company's 2018 Equity Incentive Plan but are subject to its terms, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% of shares vesting annually on the grant date anniversary, contingent on continued employment with Travere.

Travere Therapeutics (NASDAQ: TVTX) announced that its Board's Compensation Committee has granted inducement equity awards to 15 new employees on June 10, 2025. The grants consist of restricted stock units (RSUs) covering 81,100 shares of common stock. These RSUs were granted outside of the company's 2018 Equity Incentive Plan but are subject to its terms, serving as material inducements for new employee recruitment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% of shares vesting annually on the grant date anniversary, contingent on continued employment with Travere.

Travere Therapeutics (NASDAQ: TVTX) will present three abstracts on FILSPARI (sparsentan) at the International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. New data from the Phase 2 SPARTAN Study demonstrates FILSPARI's antifibrotic and anti-inflammatory effects in IgA nephropathy (IgAN), showing rapid and sustained reductions in urinary BAFF and sC5b9, along with decreases in proinflammatory and profibrotic biomarkers. The presentations will include biomarker analysis revealing intrarenal effects in IgAN, proteinuria target achievements in FSGS patients compared to irbesartan, and direct effects on glomerular capillary wall permeability in nephrotic syndrome models. Chief Medical Officer Jula Inrig emphasized that these findings suggest potential disease-modifying effects in IgA nephropathy.

Travere Therapeutics (NASDAQ: TVTX) has launched 'Play It Forward,' a new awareness campaign for focal segmental glomerulosclerosis (FSGS), a rare kidney disease that can lead to kidney failure. The campaign debuts on the first-ever FSGS Awareness Day and features a collaborative anthem by Grammy-winning producer Brian Kennedy and singer-songwriter David Rush, both FSGS patients. The initiative encourages the FSGS community to share their creative expressions and personal stories on social media using the campaign's soundtrack. The campaign includes a hero video documenting Kennedy and Rush's FSGS journeys and the anthem's creation, aiming to transform isolation into connection and inspire others living with FSGS. The campaign can be followed via #PlayitForwardFSGS and at RKDandMe.com/PlayItForwardFSGS.

Travere Therapeutics (TVTX) will present seven abstracts at the ERA Congress in Vienna showcasing new data for FILSPARI in treating IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Key findings include: The Phase 2 SPARTACUS Study showed FILSPARI provided meaningful benefits when replacing RASi in IgAN patients on SGLT2i therapy. The PROTECT Study's open-label extension demonstrated significant proteinuria reduction in patients switching from irbesartan to FILSPARI. Preclinical studies revealed FILSPARI's protective role against IgA deposition and its ability to maintain glomerular filtration barrier integrity. The DUPLEX Study showed patients achieved proteinuria remission faster and more frequently with FILSPARI compared to irbesartan. The presentations will take place June 4-7, 2025, highlighting FILSPARI's potential as a foundational therapy for rare kidney diseases.

CSL Vifor announced that FILSPARI® (sparsentan) has received recommendation from England's National Institute for Health and Care Excellence (NICE) for treating IgA nephropathy. The treatment is approved for adults with urine protein excretion ≥1.0 g/day or urine protein-to-creatinine ratio ≥0.75 g/g. This marks the first non-immunosuppressive dual-action therapy recommended for this condition, which affects over 22,000 adults in England. The recommendation follows MHRA authorization in April 2025, with commercial availability expected from July 2025. IgA nephropathy, the most common primary glomerular disease worldwide, leads to kidney failure in 30-40% of patients within 10 years of diagnosis if not properly controlled. The NICE decision requires NHS England to fund the treatment within 90 days of final publication, expected on June 27, 2025.